"目录号: HY-14546
GPCR/G ProteinNeuronal Signaling-
Aripiprazole(Abilify)是人5-HT1A受体部分激动剂，Ki为4.2 nM。
5-HT Receptor
相关产品
Clozapine N-oxide-Chlorpromazine hydrochloride-Pimavanserin-Brexpiprazole-Lorcaserin Hydrochloride-Scopolamine hydrobromide-Cariprazine hydrochloride-Harmine-Lu AE58054 Hydrochloride-TG6-10-1-Perphenazine-Ferulic acid sodium-Olanzapine-Sertindole-B-HT 920-
生物活性
Description
Aripiprazole(Abilify) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM. IC50 Value: 4.2 nM(Ki)Target: 5-HT ReceptorAripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.
Clinical Trial
NCT00468130
University of Medicine and Dentistry of New Jersey-Rutgers, The State University of New Jersey
Autism
May 2006
NCT01001702
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
April 2006
Phase 3
NCT00276978
University Hospital Freiburg
Therapy-resistant Depression
June 2005
Phase 3
NCT03172871
Otsuka Beijing Research Institute
Schizophrenia
May 31, 2017
Phase 3
NCT02501109
CMG Pharmaceutical Co. Ltd
Schizophrenia
October 2015
Phase 1
NCT00497055
San Francisco Department of Public Health-National Institute on Drug Abuse (NIDA)
Substance Abuse-HIV Infections
March 2009
Phase 2
NCT00947154
Stanford University
Trichotillomania
July 2009
NCT01727713
Otsuka Pharmaceutical Development & Commercialization, Inc.
Tourette's Disorder-Tic Disorder
January 2013
Phase 3
NCT01338298
University of Maryland
Hyperprolactinemia
January 2011
NCT00250705
University of Iowa-Bristol-Myers Squibb
Conduct Disorder
November 17, 2004
Phase 4
NCT00198055
Indiana University School of Medicine-Bristol-Myers Squibb-Indiana University
Asperger's Disorder-Pervasive Developmental Disorder
January 2005
Phase 2
NCT02069977
Yoo-Sook Joung-Korea Otsuka International Asia Arab-Samsung Medical Center
Autism
February 2014
Phase 4
NCT00374348
Jamaica Hospital Medical Center-Bristol-Myers Squibb-Department of Psychiatry, Jamaica Hospital Medical Center-Research Division
Schizophrenia OCD-Obsessive Compulsive Disorder
March 2005
NCT00220636
St. Luke's-Roosevelt Hospital Center-Bristol-Myers Squibb
Depressive Disorder, Major
March 2005
Phase 4
NCT00208533
Drexel University College of Medicine-Drexel University
Autism
February 2004
Phase 2
NCT00308074
Cambridge Health Alliance-Bristol-Myers Squibb
Autism-Asperger's Disorder-Pervasive Developmental Disorder
February 2006
Phase 2
NCT00556140
Massachusetts General Hospital-Bristol-Myers Squibb
Psychotic Depression
June 2003
Phase 3
NCT00705783
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
July 2008
Phase 3
NCT01714011
University of Malaya
Schizophrenia
May 2009
Phase 4
NCT01416441
Otsuka Pharmaceutical Development & Commercialization, Inc.
Tourette's Disorder
August 2011
Phase 3
NCT00420459
Indiana University School of Medicine-Indiana University
Fragile X Syndrome
April 2007
Phase 2
NCT02697045
Abdi ?brahim Otsuka
Schizophrenia
April 2016
Phase 4
NCT00102063
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
July 2004
Phase 3
NCT01552772
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
January 2012
Phase 1
NCT00608543
University of Texas Southwestern Medical Center-Bristol-Myers Squibb
Major Depressive Disorder
October 2005
Phase 4
NCT01509053
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
January 2012
Phase 3
NCT00194038
University Hospitals Cleveland Medical Center-Bristol-Myers Squibb
Bipolar Disorder
April 2004
Phase 4
NCT00665444
University of Pittsburgh-Bristol-Myers Squibb
Bipolar Disorder-Metabolic Syndrome
April 2008
NCT02435836
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
April 1998
Phase 3
NCT01386086
Lawson Health Research Institute-Bristol-Myers Squibb
Postpartum Depression
June 2011
Phase 3
NCT00619190
University of North Carolina, Chapel Hill-Bristol-Myers Squibb
Autistic Disorder-Asperger Syndrome-Autism Spectrum Disorder
January 2006
Phase 2
NCT01696617
Seoul National University Hospital-Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
February 2012
Phase 4
NCT00362271
Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy
August 2006
Phase 1
NCT01942148
Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
August 2010
Phase 3
NCT00545467
National Taiwan University Hospital-National Science Council, Taiwan-Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
DSM-IV Schizophrenia-Schizoaffective Disorder
August 2007
Phase 4
NCT01188668
Pfizer
Pharmacokinetics-Cytochrome P-450 CYP2D6-CYP3A4 Protein, Human
August 2010
Phase 4
NCT00361790
Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy
August 2006
Phase 1
NCT00731549
Otsuka Pharmaceutical Development & Commercialization, Inc.-Covance
Schizophrenia
December 2008
Phase 3
NCT01870999
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
November 2007
Phase 1
NCT00194077
University Hospitals Cleveland Medical Center-Bristol-Myers Squibb
Bipolar Disorder
August 2004
Phase 3
NCT01085383
University of Oxford-National Institute for Health Research, United Kingdom
Hyperprolactinemia
April 2010
Phase 4
NCT00328367
Seoul National University Hospital-Korea Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
December 2005
Phase 4
NCT01411930
Veterans Medical Research Foundation-Bristol-Myers Squibb
Diabetes
March 2009
Phase 4
NCT01028820
University of North Carolina, Chapel Hill-Duke University-National Institute of Mental Health (NIMH)
Autism Spectrum Disorder
August 2009
Phase 4
NCT02918370
University of Texas Southwestern Medical Center
Bipolar Disorder-Alcoholism-Alcohol Abuse
November 2016
Phase 3
NCT00312598
University of North Carolina, Chapel Hill-Bristol-Myers Squibb
Schizophrenia-Schizoaffective Disorder-Schizophreniform Disorder-Mood Disorders
August 2005
Phase 4
NCT02949752
Institute of Mental Health, Singapore
Antipsychotics Weight Gain
August 2016
Phase 4
NCT00325689
Otsuka Pharmaceutical Development & Commercialization, Inc.-Otsuka America Pharmaceutical